AGP Picks
View all

CD79a antibody market seen reaching $2 billion by 2030

2 hours ago
CD79a antibody market seen reaching $2 billion by 2030
By AI, Created 17:30 UTC, Nov 19, 2026, AGP -

The CD79a antibody market is projected to grow from $1.22 billion in 2025 to $2 billion by 2030, driven by demand for precision diagnostics, personalized medicine and antibody engineering. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - CD79a antibodies are used to identify B-cell lineage, helping researchers and clinicians distinguish B-cell neoplasms from other blood cancers. - The market’s growth reflects broader demand for precision diagnostics and targeted therapies in hematologic disease. - Expansion in this market can support faster diagnosis, more specific research tools and more advanced treatment pathways.

What happened: - The CD79a antibody market is projected to rise from $1.22 billion in 2025 to $1.35 billion in 2026. - The market is forecast to reach $2 billion by 2030. - The 2025-2026 growth rate is projected at 10.5%. - The 2026-2030 growth rate is projected at 10.2%. - The Business Research Company released a report on the market titled Cluster Of Differentiation (CD) 79a Antibody Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - The report includes market forecasts, trend analysis and regional coverage across Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also offers a free sample of the report and the full market report.

The details: - Growth from 2025 to 2026 is tied to expanded use of immunohistochemistry in pathology. - Other growth drivers include rising incidence of B-cell malignancies, more academic research in immunology, broader access to monoclonal antibody production technologies and greater use of flow cytometry. - Future growth is expected to come from stronger demand for precision diagnostics. - Additional drivers include increased research in personalized medicine, higher investment in antibody engineering, wider use of multiplex diagnostic assays and advances in translational research programs. - Key trends include greater use of recombinant antibody formats. - The market is also seeing broader use of CD79a in diagnosing hematologic cancers. - Demand is rising for highly specific B-cell markers. - Automated immunoassay platforms are becoming more common. - Antibody validation standards are becoming stricter. - CD79a is a monoclonal antibody that targets the CD79a protein, a core part of the B-cell antigen receptor complex on B lymphocytes. - The antibody helps assess B-cell development and function in immunology and pathology research. - The antibody is also used in clinical and scientific settings. - In December 2024, the American Society of Gene & Cell Therapy reported that the FDA approved six gene therapy products in 2023, up from five in 2022.

Between the lines: - The market’s momentum tracks with a wider shift toward targeted and personalized medicine. - More regulatory approvals for advanced therapies can reinforce demand for diagnostic tools that help match treatment to disease type. - North America’s lead reflects established healthcare infrastructure and a strong research base. - Asia-Pacific’s expected growth suggests rising spending on healthcare and diagnostics, plus broader adoption of advanced testing.

What's next: - The market is expected to keep expanding through 2030 as precision medicine and translational research gain traction. - Recombinant formats, automated platforms and multiplex assays are likely to play a larger role in product development and adoption. - Regional growth should remain strongest in Asia-Pacific as investment and research activity increase.

The bottom line: - CD79a antibodies are moving from a niche research tool to a more important part of cancer diagnostics and precision medicine, and the market outlook remains firmly upward.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Middle East Culture Guide

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Middle East Culture Guide

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.